CRChandana Roy

Chandana Roy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chandana Roy has a total of 2 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Rauwolfia serpentina in P-Glycoprotein Inhibition of Cancer & Diabetes - A Computational Study

    by Chandana Roy, Sayak Ganguli, Pratiti Ghosh

    Background: The efficient treatment of cancer and diabetes is often constrained by reduced permeation of chemotherapeutic and antidiabetic medications due to p-glycoprotein-mediated efflux, impeding their therapeutic potential and necessitating higher doses or prolonged treatments, which can lead to increased toxicity and financial burden. Ayurveda, an ancient holistic healthcare system, advocates the use of herbal remedies for various ailments. Objective: This study aims to explore the potential of Rauwolfia serpentina and other selected antidiabetic and anticancer medicinal herbs as inhibitor of p-glycoprotein. Materials and Methods: Druggability and pharmacokinetic profile of 185 herbal constituents were evaluated and their binding affinity were interpreted against 6C0V structure of p-glycoprotein utilizing molecular docking with CDOCKER program of Discovery Studio. The stability of the docked complex was validated using molecular dynamics simulation for 40 nanoseconds. ChemMine software was employed for clustering p-glycoprotein herbal inhibitors against standard drug verapamil on the basis of physicochemical properties. Results: Docking analyses revealed that deserpidine and ajmalicine from Rauwolfia serpentina exhibited strong favourable binding interactions with p-glycoprotein, along with other herbal compounds viz., hydrastine from Hydrastis canadensis, palmatine from Tinospora cordifolia and hexadecanoic acid 2-hydroxy-1(hydroxymethyl)ethyl ester from Ipomoea aquatica. Conclusion: This study underscores the potential of combining Rauwolfia serpentina and other medicinal herbs with allopathic drugs to augment their bioavailability and efficacy, providing a novel avenue for advancing therapeutic strategies in oncology and diabetes management. Further experimental validation is necessary to confirm the clinical relevance of these findings.


  • Open Access

    Exploring the Potential of Phytoconstituents for Immunomodulation as Natural Inhibitors of P-glycoprotein - A Computational Study

    by Chandana Roy, Sayak Ganguli, Pratiti Ghosh

    Background: P-glycoprotein is an efflux transporter found on the walls of internal organs that interact with the environment, to reduce bioavailability of xenobiotics and chemotherapeutic drugs. Co-administration of herbal medicinal components as modulators or inhibitors may configure the transporter in favour of the drug, thus restricting its expulsion. Aim: The present study aims to explore such herbal medicinal components as potential p-glycoprotein inhibitors thus analyzing the possibility for retaining co-administered immunomodulatory medicines within target cells. Methods: Druggability and pharmacokinetic attributes of the natural compounds were analyzed. Molecular docking using CDOCKER program of Discovery studio (version 2019-21) was utilized to analyze the binding affinity between the natural compounds and 6C0V receptor. Molecular dynamics simulation was employed to evaluate the stability of potential binding compounds. Results: Molecular docking analyses of 462 components from 30 herbs revealed that the inhibitors viz., chelidonine, dihydroberberine, stylopine, fumariline from Chelidonium majus; akuammigine, echitamine from Alstonia scholaris; arjunone from Terminalia arjuna and pareirubrine A from Cissampelos pareira displayed strong binding affinity towards p-glycoprotein. Conclusion: These lead compounds viz., chelidonine, akuammigine and echitamine bearing the maximum binding potency, are known components of immune enhancing herbs. We propose that these molecules may be used in conjunction with immunomodulatory drugs to enhance their bioavailability.

  • Open Access

    Co-administration of herbal inhibitors of P-glycoprotein with renal drugs enhance their bioavailability– In silico approach

    by Chandana Roy, Pratiti Ghosh

    Introduction: Multidrug resistance (MDR) is primarily associated with reduced intracellular drug accumulation owing to overexpression of p-glycoprotein, an active efflux transporter. Competitive inhibition or allosteric modulation of p-glycoprotein may alter the pharmacokinetics of the drugs that serve as substrates, resulting in enhanced drug bioavailability and tissue penetration. This study endeavors to assess the efficacy of the components of reno-protective herbs in the inhibition of p-glycoprotein activity thereby enhancing the possibility of the retention of co-administered renal medications inside the target cells. Methods: Drug-likeness and pharmacokinetic properties were determined to ensure the safety and efficacy of herbal constituents. Molecular docking employing the CDOCKER module of Discovery Studio was performed to investigate the binding affinity between the active constituents and the p-glycoprotein receptor (6C0V). Molecular dynamics simulation was utilized to further assess the stability of the complex of receptors with the component bearing its maximal affinity. Results: The analyses suggested that the inhibitors viz., atisine, kutkin, and embelin from Aconitum heterophyllum, phylloquinone from Calendula officinalis, stigmasterol from Paederia foetida, and convallamarogenin from Convallaria majalis demonstrated maximum binding affinity towards p-glycoprotein. Conclusion: Atisine may thus be identified as the lead compound in the augmentation of drug bioavailability inside the cell, along with its reno-protective efficacy.